Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$894000.0.

  • BridgeBio Pharma's Cash from Financing Activities fell 22644.98% to -$894000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $835.4 million, marking a year-over-year increase of 20940.62%. This contributed to the annual value of $748.5 million for FY2024, which is 6575.84% up from last year.
  • BridgeBio Pharma's Cash from Financing Activities amounted to -$894000.0 in Q3 2025, which was down 22644.98% from $302.0 million recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Cash from Financing Activities high stood at $547.9 million for Q1 2021, and its period low was -$135.5 million during Q3 2021.
  • Over the past 5 years, BridgeBio Pharma's median Cash from Financing Activities value was $1.4 million (recorded in 2022), while the average stood at $120.3 million.
  • Per our database at Business Quant, BridgeBio Pharma's Cash from Financing Activities tumbled by 496901.51% in 2021 and then soared by 9400562.5% in 2023.
  • BridgeBio Pharma's Cash from Financing Activities (Quarter) stood at $325.4 million in 2021, then plummeted by 98.04% to $6.4 million in 2022, then crashed by 170.93% to -$4.5 million in 2023, then surged by 10578.24% to $473.9 million in 2024, then tumbled by 100.19% to -$894000.0 in 2025.
  • Its last three reported values are -$894000.0 in Q3 2025, $302.0 million for Q2 2025, and $60.3 million during Q1 2025.